Celltrion and Teva Announce FDA Approval of TRUXIMA (rituximab-abbs), a Biosimilar to RITUXAN, for Three Non-Hodgkin?s Lymphoma Indications
- TRUXIMA is the first rituximab biosimilar to be approved in the United States?
INCHEON, South Korea & JERUSALEM--Celltrion, Inc.?(KRX:068270) and?Teva Pharmaceutical Industries Ltd.?(NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved TRUXIMA?(rituximab-abbs), a monoclonal antibody (mAb) biosimilar to RITUXAN?[1]?(rituximab) for the treatment of adult patients in three indications:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non?Hodgkin?s lymphoma (NHL) as a single agent.
- ?Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- ?Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.